Rogosin Institute-Nephrology Foundation Of Brooklyn South is a medicare approved dialysis facility center in Brooklyn, New York and it has 30 dialysis stations. It is located in Kings county at 1845 Mcdonald Avenue, Brooklyn, NY, 11223. You can reach out to the office of Rogosin Institute-Nephrology Foundation Of Brooklyn South at (646) 317-0750. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Rogosin Institute-Nephrology Foundation Of Brooklyn South has the following ownership type - Non-Profit. It was first certified by medicare in March, 1984. The medicare id for this facility is 332522 and it accepts patients under medicare ESRD program.
| Name | Rogosin Institute-Nephrology Foundation Of Brooklyn South |
|---|---|
| Location | 1845 Mcdonald Avenue, Brooklyn, New York |
| No. of Dialysis Stations | 30 |
| Medicare ID | 332522 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | Yes |
| 1845 Mcdonald Avenue, Brooklyn, New York, 11223 | |
| (646) 317-0750 | |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| NPI Number | 1073850384 |
| Organization Name | Rogosin Institute Nfb South |
| Doing Business As | The Rogosin Institute Inc |
| Address | 1845 Mcdonald Ave Brooklyn, New York, 11223 |
| Phone Number | (718) 336-9700 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| NPI Number | 1982618591 |
| Doing Business As | Nephrology Foundation Of Brooklyn |
| Address | 1845 Mcdonald Ave Brooklyn, New York, 11223 |
| Phone Number | (718) 336-9700 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 80% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 8% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 68% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 27% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 14% |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 59% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 20% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 27% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 76% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 24% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 64% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 23% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 12% |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 113 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 24 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 211 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 2039 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 4 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 28 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Rogosin Institute-Nephrology Foundation Of Brooklyn South with elevated calcium levels.
| Patients with hypercalcemia | 216 |
| Hypercalcemia patient months | 2092 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
| Patients with Serumphosphor | 223 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 20 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 28 |
| Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 154 |
| Patient months included in arterial venous fistula and catheter summaries | 1497 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 81 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 170 |
| Hospitalization Rate in facility | 190.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 273 |
| Hospitalization Rate: Lower Confidence Limit | 140.3 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Rogosin Institute-Nephrology Foundation Of Brooklyn South were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 30.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.2 |
| Readmission Rate: Lower Confidence Limit | 22 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients with recent-onset type 1 diabetes. Investigators have therefore suggested that HLA hyperexpression may be an important first step in the development of type 1 diabetes.
They hoisted signs warning of corporate greed, raised their fists in solidarity against government tyranny and blasted fight songs over portable speakers.
A new active pharmaceutical ingredient may help against severe forms of testicular cancer, which only respond inadequately to other therapies.
› Verified 9 days ago